Autologous bone marrow aspirate for treatment of superficial digital flexor tendonitis in 105 racehorses

Abstract

To evaluate a treatment protocol whereby superficial digital flexor (SDF) tendonitis in Thoroughbred and Standardbred racehorses was treated with autologous bone marrow aspirate (ABMA) obtained from the sternebrae. This treatment was combined with desmotomy of the accessory ligament of the SDF tendon (DAL-SDFT) in selected cases. Medical records of 105 horses treated using the reported protocol were reviewed. Signalment, history and details of treatment were recorded. Racing records were reviewed and performance recorded. Of Thoroughbreds, 82 per cent had one or more starts within the follow-up period and 59 per cent had five or more starts. Of Standardbreds, 76 per cent had one or more starts and 62 per cent had five or more starts. A statistically significant difference was found when comparing race starts between sexes, with females having less starts than males (≥1start P=0.017 and ≥5 starts P=0.008, respectively). The proportions of horses having one or more starts and five or more starts did not differ significantly if a DAL-SDFT was performed or not (P=0.31 and 0.63, respectively). Horses with a core lesion in the body of the SDFT have a good prognosis for return to racing following intralesional ABMA injection. Addition of DAL-SDFT to the treatment regimen did not significantly influence outcome.

Triggering the activation of Activin A type II receptor in human adipose stem cells towards tenogenic commitment using mechanomagnetic stimulation

“…13,14,20,21 This raised the hypothesis that this approach can be extended to other tissues of the musculoskeletal system, such as tendons, where stem cell therapies have already been shown to be effective as veterinary treatments and would benefit from further control of differentiation. 22 In this study, we have identified the cell surface receptors which are likely to be mechano-magnetically targeted and investigated if we can activate cell signalling pathways downstream.…”

Randomized controlled trial demonstrates the benefit of RGTA® based matrix therapy to treat tendinopathies in racing horses

“…This limit is due to the lack of owner compliance and represents a weakness of this study since the statistical analysis was limited by the small population. To our knowledge, we identified two field randomized clinical trials showing some efficacy of autologous MSC cells [ 13 , 15 ]. Dyson (2004) was not able to perform a randomized placebo controlled trial because of this inherent client limitation [ 5 ].…”

“…Most previous published data referred to retrospective [ 11 ], uncontrolled [ 13 , 15 , 16 , 42 ] or matched [ 5 , 9 , 10 , 22 ] trials. A study published by Smith et al (2013), described a randomized and controlled clinical trial, to estimate the efficacy of autologous bone marrow stem cells on naturally occurring tendinopathy, but no performance follow-up was presented [ 43 ].…”

“…Most clinical trials previously published were performed on flat and National Hunt racehorses or sport horses [ 2 , 5 , 10 , 11 , 16 , 41 , 43 ]. Few were made on Standardbreds [ 9 , 11 , 42 , 45 ], and only three considered superficial digital flexor tendonitis [ 15 , 42 , 45 ]. The choice of ST in this study was based on the large population available in France, the easy accessibility to performance data, and the simple management of racing career (ST resume racing as soon as possible and can race all year long).…”

Qualitative comparison between equine bone marrow- and blood-derived autologous conditioned serum

“…Charakteristisch für das ACS ist eine Anreicherung des entzündungshemmenden Interleukin-1 Rezeptor-Antagonisten (IL-1Ra), welcher unter anderem von verschiedenen Zelltypen aus dem Blut und Knochenmark synthetisiert und freigesetzt wird (Danis et al 1995, Burger and Dayer 2000, Prockop und Oh 2012, Isoda et al 2014 (Fortier et al 2010, Ishihara et al 2013, Chahla et al 2016, bei der zweiten liegt der Fokus auf den Zellmediatoren aus dem Knochenmarksüberstand (KMÜ), der entweder Thrombozyten und Leukozyten enthält oder azellulär ist (Smith et al 2006, Künneke et al 2008, Schnabel et al, 2008, und die letzte nutzt das gesamte Knochenmarkaspirat ohne weitere Verarbeitung (Herthel 2001, Hall et al 2013, Russell et al 2016 (Burnouf et al 2008). Ziel war eine Zelllyse in dieser KMÜ Fraktion zu induzieren (LysKMÜ), damit die in den Zellen enthaltenen Wachstumsfaktoren freigesetzt werden.…”